But what is the definition of rapid.
And do children's hearts often rapidly improve when they are clinically improving from MIS?
These are questions I don't know the answer to. Whether the cells caused this or it was going to happen in its own is pure conjecture.
For example: If they gave the cells to a deteriorating child and the child continued to deteriorate, would we say the cells caused this or was it happening already? You can't say.
It does add to my intrigue over the heart failure applications. I've mentioned before I'd love to see a trial with systemic infusion rather than intramyocardial.
We'll likely get that study.
All purely IMO
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-52
-
- There are more pages in this discussion • 372 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |